EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Potent and durable control of mesothelin-expressing tumors by a novel T cell-secreted bi-specific engager

Paris Kosti, Johan Abram-Saliba, Laetitia Pericou-Troquier, Sarah Pavelot, Tiphaine Ruggeri, Marc Laffaille, Melita Irving, George Coukos, Evripidis Lanitis, Steven M Dunn

Journal for ImmunoTherapy of Cancer · 2025

DOI: 10.1136/jitc-2024-010063 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2025. Verfasst von Paris Kosti und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Ludwig Cancer Research Lausanne Branch, University of Lausanne, Lausanne, Switzerland. Hauptthemen laut MEDLINE: T-Lymphocytes, GPI-Linked Proteins, Receptors, Chimeric Antigen, Immunotherapy, Adoptive. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Swiss National Science Foundation, Ludwig Cancer Research, Fondazione Teofilo Rossi di Montelera e di Premuda.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The glycosylphosphatidylinositol-anchored cell surface protein mesothelin (MSLN) shows elevated expression in many malignancies and is an established clinical-stage target for antibody-directed therapeutic strategies. Of these, the harnessing of autologous patient T cells via engineered anti-MSLN chimeric antigen receptors (CAR-T) is an approach garnering considerable interest. Although generally shown to target tumor MSLN safely, CAR-T trials have failed to deliver the impressive curative or response metrics achieved for hematological malignancies using the same technology. A need exists, therefore, for improved anti-MSLN molecules and/or more optimal ways to leverage immune effector cells.

Methods

We performed ELISA, label-free kinetic binding assays, FACS, Western blotting, and transient recombinant MSLN expression to characterize the recognition properties of a novel CAR-active human scFv clone, LABC-13F08. To investigate T cell redirection, we conducted kinetic IncuCyte co-culture killing assays using transduced primary T cells and MSLN + target cell lines and assessed levels of activation markers and effector cytokines. The antitumor potential of LABC-13F08 formatted as a bispecific engager (BiTE) was evaluated in vivo using transduced human primary T cells and immunocompromised NSG mice xenografted with ovarian, mesothelioma, and pancreatic MSLN + tumor cell lines.

Results

The LABC-13F08 scFv is highly unusual and distinct from existing (pre)clinical anti-MSLN antibody fragments, exhibiting an absolute requirement for divalent cations to drive MSLN recognition. As a monovalent BiTE, LABC-13F08 demonstrates robust in vitro potency. Additionally, primary human T cells engineered for constitutive secretion of the 13F08 BiTE exhibit strong antitumor activity toward in vivo ovarian and mesothelioma xenograft models and show encouraging levels of monotherapy control in a challenging pancreatic model. LABC-13F08 BiTE secreted from engineered T cells (BiTE-T) can both recruit non-engineered bystander T cells and also induce activation-dependent MSLN-independent bystander killing of cells lacking cognate antigen. To address safety concerns, 13F08 BiTE-T cells can be rapidly targeted for clearance via a molecular “off” switch.

Conclusions

The novel LABC-13F08 scFv exhibits a mode of binding to MSLN which is not observed in typical anti-MSLN antibodies. Efficacious targeting by a T cell secreted engager would represent a clinically differentiated approach for the treatment of MSLN + tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

T-LymphocytesGPI-Linked ProteinsReceptors, Chimeric AntigenImmunotherapy, AdoptiveMesothelinHumansAnimalsMiceFemaleXenograft Model Antitumor AssaysCell Line, Tumor

Stichwörter der Autor:innen

Adoptive cell therapy - ACTBispecific T cell engager - BiTEImmunotherapySolid tumorT cell

Substanzen

MesothelinMSLN protein, humanGPI-Linked ProteinsReceptors, Chimeric AntigenMsln protein, mouse

Autor:innen und Institutionen

  • Department of Oncology, Ludwig Cancer Research Lausanne Branch, University of Lausanne, Lausanne, Switzerland.
  • Department of Oncology, CHUV, Lausanne, Switzerland.
  • Department of Oncology, Ludwig Cancer Research Lausanne Branch, University of Lausanne, Lausanne, Switzerland steven.dunn@chuv.ch.

Förderung

  • Swiss National Science Foundation
  • Ludwig Cancer Research
  • Fondazione Teofilo Rossi di Montelera e di Premuda

Zitieren

APA

Kosti, P., Abram-Saliba, J., Pericou-Troquier, L., Pavelot, S., Ruggeri, T., Laffaille, M., Irving, M., Coukos, G., Lanitis, E., & Dunn, S. M. (2025). Potent and durable control of mesothelin-expressing tumors by a novel T cell-secreted bi-specific engager. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-010063

Vancouver

Kosti P, Abram-Saliba J, Pericou-Troquier L, Pavelot S, Ruggeri T, Laffaille M, et al. Potent and durable control of mesothelin-expressing tumors by a novel T cell-secreted bi-specific engager. Journal for ImmunoTherapy of Cancer. 2025. doi:10.1136/jitc-2024-010063

BibTeX
@article{Kosti2025,
  author = {Kosti, Paris and Abram-Saliba, Johan and Pericou-Troquier, Laetitia and Pavelot, Sarah and Ruggeri, Tiphaine and Laffaille, Marc and Irving, Melita and Coukos, George and Lanitis, Evripidis and Dunn, Steven M},
  title = {Potent and durable control of mesothelin-expressing tumors by a novel T cell-secreted bi-specific engager},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  doi = {10.1136/jitc-2024-010063}
}
Kostenlos starten →